title: Infliximab treatment for symptomatic Crohn's disease strictures.
abstract: BACKGROUND
  Some reports have suggested that infliximab may induce obstructive symptoms and, although there is no firm evidence, it is usually contra-indicated in-patients with Crohn's disease (CD) and strictures.
  
  
  OBJECTIVE
  To evaluate the effect of infliximab on symptomatic strictures of the small intestine in CD and to identify predictive factors of clinical response.
  
  
  METHODS
  This retrospective study included symptomatic patients treated with infliximab after conventional treatment had failed. The short-term (week 8) and long-term results were classified according to predefined criteria as complete, partial response, or failure.
  
  
  RESULTS
  Before infliximab, 18 patients had complete obstruction or intermittent chronic abdominal pain. Fourteen patients were treated by corticosteroids and 13 received immunosuppressive drugs. At week 8, complete, partial response and failure were observed in 10, 7 and 1 patients, respectively. Fourteen patients continued maintenance infliximab treatment after week 8. During the most recent evaluation (median follow-up: 18 months), 8 patients were on maintenance infliximab treatment; only eight were still on prednisone; there were five complete responses, 10 partial responses and three failures. Initiating prednisone or increasing its dosage was the only factor associated with a short-term complete response.
  
  
  CONCLUSIONS
  Infliximab may be effective in patients with symptomatic strictures from CD, and should be tested before considering surgery.
authors.affiliation: Service d'Hépato-gastroentérologie, Hôpital Bichat, 46 rue Huchard, 75877 Paris cedex 18, France. anne-laure.pelletier@bch.aphp.fr
authors.forename: A-L
authors.initials: AL
authors.lastname: Pelletier
authors.forename: B
authors.initials: B
authors.lastname: Kalisazan
authors.forename: J
authors.initials: J
authors.lastname: Wienckiewicz
authors.forename: N
authors.initials: N
authors.lastname: Bouarioua
authors.forename: J-C
authors.initials: JC
authors.lastname: Soulé
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003251:Constriction, Pathologic / Q000188:drug therapy / Q000209:etiology; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D007077:Ileal Diseases / Q000188:drug therapy* / Q000209:etiology; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab